Testing SM17 for moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called SM17 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if SM17 can reduce itching and skin symptoms when topical treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had eczema for at least 1 year and it covers at least 10% of your body.
- Your eczema is moderate to severe, with an EASI score of 16 or higher and an IGA score of 3 or higher.
- Your itching is at least a 4 out of 10 on a scale over the past week.
- Topical treatments like steroid creams have not worked well enough or are not suitable for you.
- You agree to use birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
This study tests an injection called ADSTEM for people with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams or other treatments. The goal is to see if it can help reduce symptoms like itching and rash.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.